Navigation Links
INVO Bioscience Announces First Shipments of INVOcell Into Bolivia
Date:12/21/2010

BEVERLY, Mass., Dec. 21, 2010 /PRNewswire/ -- INVO Bioscience, Inc. (OTC Bulletin Board: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced the initial shipments of the INVOcell device into Bolivia.  The initial order of INVOcell devices was purchased by The National Center for Fertility and Sterility (CENALFES). Under the direction of clinic director Dr. Joaquin Lopez Arana and embryologist Dr. Patricia Frias, CENALFES is the largest infertility treatment center in Bolivia, having assisted more than 4,000 infertility patients over the past 20 years resulting in more than 1,500 births. Bolivia represents the fourth country in South America where fertility clinics have ordered INVOcell.  

Bolivia has approximately 5 fertility centers licensed to perform assisted reproductive procedures.  According to the Bolivian Health Ministry there are more than 1.8 million infertile couples in Bolivia, however less than 1,000 couples per year engage in assisted reproductive procedures, largely due to costs. Clinical results have demonstrated outstanding effectiveness of the INVOcell process without many of the inherent expenses associated with traditional in-vitro fertilization (IVF) procedures.

Kathleen Karloff, chief executive officer for INVO Bioscience, commented, "The company continues to execute on its stated goal of introducing the INVOcell device and process to many of the key opinion leaders throughout the world that will influence expanded acceptance and use of our products.  CENALFES is one the largest providers of infertility treatments in Bolivia, which we expect to become a strong reference to the exceptional capabilities of INVOcell. We look forward to continue working with the many physicians at CENALFES and elsewhere in Bolivia to offer the many suffering infertile patients a cost
'/>"/>

SOURCE INVO Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ambit Biosciences Initiates Two Phase I Clinical Trials
2. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
3. Cell Biosciences Announces US Patent Issuance
4. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
5. ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
11. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and AUSTIN, Texas , ... PureMHC LLC today announced they have entered into ... antibody-based immunotherapies designed to target cancers. ... peptides displayed on the surfaces of tumor cells ... targets (PTTs), derived from proteins that play a ...
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... Inc. (Nasdaq: MSON ), a developer of minimally invasive ... the ablation of tumors and worldwide for other acute health ... year ended June 30, 2009. , The Company also reported ... payment of $3.5 million was received on April 7, 2009 ...
... , SAN MATEO, Calif., Oct. 1 Corthera Inc. ... (FDA) has granted Fast Track designation to relaxin, the ... failure (AHF). The Fast Track program facilitates the development ... treat serious or life-threatening conditions and that demonstrate the ...
Cached Medicine Technology:Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 2Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 3Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 4Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 5Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 7Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 8Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 9Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 10Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 2Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 3
(Date:10/22/2014)... Hay House is pleased to announce the official ... Life (Paperback; $10.82) written by the highly esteemed Tommy Rosen, ... book is meant to help readers of all kinds end ... , Recovery 2.0 is not the average self-help book, or ... guide for what comes next. For many, Alcoholics ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Two sisters in high ... damage. Ilina and Medha Krishen use electronic stethoscopes, ... of trouble in breathing patterns or heartbeats. Ilina, ... Michigan, wanted to find a way to detect early ... Using an electronic stethoscope, Ilina recorded one breath cycle ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. ... officially tightened guidelines for health workers treating Ebola patients, now ... of a respirator at all times. The U.S. Centers ... rules after two Dallas nurses contracted Ebola while caring for ... national Thomas Eric Duncan. Nina Pham is currently being treated ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... sees telcos looking to find,viable solutions for improving public safety and network resiliency for all ... Americans, BOULDER, Colo., April 3, 2008 , WHO: ... Aztek Networks ( http://www.azteknetworks.net ), ... 20 years experience, Bruny has served as CEO of Aztek Networks, ...
... Rhytec, Inc. the pioneer,of plasma skin regeneration ... a novel thermal energy called plasma for reversing ... U.S. Food and Drug Administration (FDA),clearance to market ... is already cleared by the FDA for treating ...
... a,statement of William V. Corr, Executive Director, Campaign for ... broken Ohio,s,promise to protect its kids from tobacco by ... tobacco prevention program, run by the,Ohio Tobacco Prevention Foundation. ... carried out. More kids will become addicted to tobacco, ...
... Grubb &,Ellis Healthcare REIT, Inc. today announced the acquisition ... 3035, 3037, 3131, and 3133 Lakeland Hills Blvd., the ... buildings. Each,building has approximately 8,000 square feet of gross ... 1998 on approximately 4.64,acres, the buildings are cumulatively 90 ...
... Roy Blunt (Mo.) issued the following statement today after ... global AIDS initiative -,even though the president himself only ... the program couldn,t spend in 10,years what the majority ... more than one occasion that the president,s initiative on,fighting ...
... Disease Patients Rising, CHICAGO, April 2 ... disease and, according to the latest research,from Prevent ... number,is continuing to climb. With more than 130 ... million suffer from leading causes of vision loss ...
Cached Medicine News:Health News:Telecommunications Carriers Respond To Congress' Declaration of April as National 9-1-1 Education Month 2Health News:Telecommunications Carriers Respond To Congress' Declaration of April as National 9-1-1 Education Month 3Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 2Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 3Health News:Gov. Strickland, Legislative Leaders Break Promise to Protect Ohio's Kids from Tobacco 2Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 2Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 3Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 4Health News:Eye Disease Continuing to Increase Among Americans 2Health News:Eye Disease Continuing to Increase Among Americans 3
... Flexible excellence for patients and clinicians., ... Aestiva/5 anesthesia system, the Aestiva/5 MRI is ... systems with a fully functional, integrated ventilator. ... Gauss, 1.5 T active shielded magnet), the ...
... ventilator control panel is conveniently located on the ... angle whether standing or sitting. The ventilator control ... and numerics. The ventilator has CMV, PCV and ... available in two lengths facilitates both the placing ...
... The flexible, modular approach to meeting today's ... offers one of the best ergonomic solutions in ... to operate from any position. A revolving arm ... magazine and moveable patient cassette mean that there ...
... The Narkomed GS provides high quality ... interface. The proven technologies of the ... make the Narkomed GS user-friendly and ... high quality Narkomed GS is the ...
Medicine Products: